Our prior studies have shown that hYP218 CAR T cells, targeting the cell membrane‐proximal epitope of mesothelin, demonstrate significant anti‐tumour efficacy in preclinical models of mesothelioma, ovarian and pancreatic cancers. Here, MSLN is linked to neoplasm.